Pharmacokinetic interaction influence of other drugs on the pharmacokinetics of escitalopram. Simultaneous use of escitalopram and omeprazole 30 mg once daily results in moderate (about 50%) increase escitalopram concentration in blood plasma. Simultaneous acquisition of escitalopram and cimetidine at a dose of 400 mg twice a day anavar cycle leads to an increase (approximately 70%) escitalopram plasma concentration. Thus, it should be used with caution escitalopram simultaneously with inhibitors of cytochrome (eg, omeprazole, ezomeprozolom, fluvoxamine, lansoprazole, ticlopidine) and cimetidine. At the same time taking escitalopram and the aforementioned drugs based on monitoring of side effects may require dose reduction of escitalopram.
The drug was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS . It had also been shown to be partially successful in treating cases of osteoporosis . However, in part due to bad publicity from its illicit use by bodybuilders , production of Anavar was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals , which following successful clinical trials in 1995, released it under the tradename Oxandrin.  BTG subsequently won approvals for orphan drug status by the Food and Drug Administration for treating alcoholic hepatitis , Turner syndrome , and HIV-induced weight loss . It is also indicated as an offset to protein catabolism caused by long-term administration of corticosteroids .